PD
NRIX icon

Point72 (DIFC)’s Nurix Therapeutics NRIX Stock Holding History

Point72 (DIFC)’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2.48K Sell
269
-2,647
-91% -$27.5K ﹤0.01% 1036
2025
Q2 		$33.2K Buy
+2,916
New +$31.5K ﹤0.01% 1144

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 (DIFC)'s NRIX Position: Q3 2025 in Review

Point72 (DIFC) reduced its Nurix Therapeutics (NRIX) stake by 91% in Q3 2025, selling an estimated $27.5K and leaving 269 shares worth $2.48K. The position accounts for ﹤0.01% of the portfolio, ranked #1036.

Point72 (DIFC) first reported a position in NRIX in Q2 2025 and has held it in 2 quarters since. The position peaked at $33.2K in Q2 2025. 173 funds tracked by Wall St. Rank hold NRIX as of Q3 2025.

  • Point72 (DIFC) held 269 shares of Nurix Therapeutics worth $2.48K as of Q3 2025.
  • Point72 (DIFC) sold 2,647 Nurix Therapeutics shares in Q3 2025, an estimated $27.5K.
  • Nurix Therapeutics made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #1036 holding.
  • Point72 (DIFC) first reported a position in Nurix Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Point72 (DIFC)'s Nurix Therapeutics position peaked at $33.2K in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.